Associate Professor Joseph (Joe) Doyle

Deputy Program Director, Disease Elimination; Co-Head, Viral Hepatitis Elimination; NHMRC Clinical Research Fellow

Background

Joseph is a physician and researcher with a particular interest in the epidemiology, management and prevention of blood borne viruses (HIV, hepatitis C and hepatitis B).

With a background in clinical medicine, Joseph specialised in infectious diseases at the Alfred where he works as a consultant physician. He completed his MPH at the London School of Hygiene and Tropical Medicine and his public health fellowship was undertaken at the Victorian Infectious Diseases Reference Laboratory and Burnet Institute. His PhD at Burnet and Monash School of Population Health was focused on the effectiveness of early hepatitis C treatment.

Joseph is currently undertaking his NHMRC Postdoctoral Fellowship aiming to improve population health and treatment for hepatitis C infection at Burnet and Department of Infectious Diseases at Monash University. He is co-head of Viral Hepatitis Research and the clinical director of the hepatitis C TAP (Treatment and Prevention Study) at Burnet.

Appointments

Deputy Program Director, Disease Elimination, Burnet Institute
Co-Head, Viral Hepatitis Elimination, Burnet Institute
NHMRC Clinical Research Fellow, Monash University
Senior Research Fellow, Department of Infectious Diseases, Monash University
Honorary Research Fellow, Department of Gastroenterology, St Vincent’s Hospital Melbourne
Adjunct Senior Lecturer, School of Population Health and Preventive Medicine, Monash University
Consultant Infectious Diseases Physician, The Alfred Hospital, Victoria, Australia

Positions

2015-2016: Postdoctoral Fellowship, Department of Gastroenterology, St Vincent’s Hospital and University of Melbourne
2011-2014: PhD Candidate, Burnet Institute, Centre for Population Health
2008-2011: Infectious Diseases Fellowship undertaken at the Royal Melbourne, Alfred and St Vincent’s Hospitals, and the Victorian Infectious Diseases Reference Laboratory, Victoria, Australia

Qualifications

2015: PhD, Monash University
2014: FAFPHM, Fellow of Australasian Faculty of Public Health Medicine, Australia
2011: FRACP in Infectious Diseases, Fellow of Royal Australasian College of Physicians, Australia
2006: MPH, London School of Hygiene and Tropical Medicine, United Kingdom
2005: BA (Hons), Department of Political Science, University of Melbourne, Victoria, Australia
2002: MBBS, University of Melbourne, Australia

Awards

2017: Burnet Institute Gust-McKenzie Medal
2014: NHMRC Early Career Fellowship
2011: NHMRC Postgraduate Scholarship

Projects (22)

Current (14)

Barriers to hepatocellular carcinoma screening uptake in Victoria
Cancer information compared to Hepatitis B information to INcreAse hepatitis B testing in Melbourne’s Chinese community (CHINA-B study)
DARE C: ATAHC II Substudy
EC Australia: Eliminate Hepatitis C Australia Partnership
EC Partnership: Eliminate Hepatitis C Partnership
National COVID-19 Clinical Evidence Taskforce
Natural history and response to treatment recent hepatitis C virus infection among a cluster of HCV genotype-1b infected individuals
Optimising Quarantine Study
The elimination of hepatitis C as a global public health threat
The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)
The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19
The PharmEC REACH study
The QuickStart Study
What drives hepatitis C reinfection?

Past (4)

co-EC Study: Eliminating hepatitis C/HIV coinfection
Eliminating hepatitis C infection in Victoria through treatment scale up
Examining hepatitis C reinfection among HIV co-infected gay and bisexual men
Hepatitis B infection in Australian prisons

Publications (125)

2022 (24)

Quarantine preparedness - the missing factor in COVID-19 behaviour change? Qualitative insights from Australia.
Davis A, Munari S, Doyle J, Sutton B, Cheng A, Hellard M, Gibbs L
BMC Public Health. 2022 Sep; 22(1):1806
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort.
Bartlett SR, Verich A, Carson J, Hosseini-Hooshyar S, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Martinez M, Marks P, Dore GJ, Matthews GV, Applegate T, Martinello M
Health Sci Rep. 2022 Sep; 5(5):e719
Care Navigation Increases Initiation of Hepatitis C Treatment After Release From Prison in a Prospective Randomized Controlled Trial: The C-LINK Study.
Papaluca T, Craigie A, McDonald L, Edwards A, Winter R, Hoang A, Pappas A, Waldron A, McCoy K, Stoové M, Doyle J, Hellard M, Holmes J, MacIsaac M, Desmond P, Iser D, Thompson AJ
Open Forum Infect Dis. 2022 Aug; 9(8):ofac350
Constructing a 'target population': A critical analysis of public health discourse on substance use among gay and bisexual men, 2000-2020.
Schroeder SE, Bourne A, Doyle JS, Hellard ME, Stoové M, Pedrana A
Int J Drug Policy. 2022 Jul; 108:103808
Review of management priorities for invasive infections in people who inject drugs: highlighting the need for patient-centred multidisciplinary care.
Attwood LO, McKechnie M, Vujovic O, Higgs P, Lloyd-Jones M, Doyle JS, Stewardson AJ
Med J Aust. 2022 Jun; 217(2):107-109
Impact of COVID-19 lockdown restrictions on hepatitis C testing in Australian primary care services providing care for people who inject drugs.
Traeger MW, van Santen DK, Sacks-Davis R, Asselin J, Carter A, Doyle JS, Pedrana A, Wilkinson AL, Howell J, Thatcher R, Didlick J, Donovan B, Guy R, Hellard ME, Stoové MA; Australia Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood Borne Viruses (ACCESS).
J Viral Hepat. 2022 Jun; 29(10):908-918
Role of COVID-19 vaccine education in discharge planning to increase community vaccination coverage.
Tse WC, Fahey J, Doyle J, Hellard M, Howell J
Intern Med J. 2022 May; 52(7):1284-1285
Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort.
Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Matthews GV, Dore GJ; REACH-C Study Group
J Viral Hepat. 2022 May; 29(8):661-676
Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: An international randomised controlled trial.
Byrne CJ, Radley A, Inglis SK, Beer L, Palmer N, Duc Pham M, Allardice K, Wang H, Robinson E, Hermansson M, Semizarov D, Healy B, Doyle JS, Dillon JF
Aliment Pharmacol Ther. 2022 May; 55(12):1512-1523
The impact of point-of-care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study.
Howell J, Traeger MW, Williams B, Layton C, Doyle JS, Latham N, Draper B, Bramwell F, Membrey D, McPherson M, Roney J, Stoové M, Thompson AJ, Hellard ME, Pedrana A
J Viral Hepat. 2022 May; 29(5):375-384
Hepatitis C antibody testing among opioid agonist therapy recipients, Victoria, Australia, 2012 to 2020.
Dawe J, Wilkinson AL, Asselin J, Carter A, Pedrana A, Traeger MW, Thomas AJ, Curtis M, Cooper M, Howell J, Doyle JS, Hellard ME, Stoové M; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood borne viruses and sexually transmissible infections (ACCESS).
Int J Drug Policy. 2022 Apr; 104:103696
Hepatitis B and pregnancy: understanding the experiences of care among pregnant women and recent mothers in metropolitan Melbourne.
Ahad M, Wallace J, Xiao Y, van Gemert C, Bennett G, Darby J, Desmond P, Hall S, Holmes J, Papaluca T, Glasgow S, Thompson A, Hellard M, Doyle J, Howell J
BMC Public Health. 2022 Apr; 22(1):817
Randomised controlled trial of active case management to link hepatitis C notifications to treatment in Tasmania, Australia: a study protocol.
Marukutira T, Moore KP, Hellard M, Richmond J, Turner K, Pedrana AE, Melody S, Johnston FH, Owen L, Van Den Boom W, Scott N, Thompson A, Iser D, Spelman T, Veitch M, Stoové MA, Doyle J
BMJ Open. 2022 Mar; 12(3):e056120
Hepatitis C incidence among patients attending primary care health services that specialise in the care of people who inject drugs, Victoria, Australia, 2009 to 2020.
Wilkinson AL, van Santen DK, Traeger MW, Sacks-Davis R, Asselin J, Scott N, Harney BL, Doyle JS, El-Hayek C, Howell J, Bramwell F, McManus H, Donovan B, Stoové M, Hellard M, Pedrana A
Int J Drug Policy. 2022 Mar; 103:103655
Understanding how to live with hepatitis B: a qualitative investigation of peer advice for Chinese people living with hepatitis B in Australia.
Wallace J, Xiao Y, Howell J, Thompson A, Allard N, Adamson E, Richmond J, Hajarizadeh B, Eagle M, Doyle J, Hellard M
BMC Public Health. 2022 Mar; 22(1):536
Interventions to eliminate hepatitis C: which ones suit your community?
Wade AJ, Doyle JS
Lancet Gastroenterol Hepatol. 2022 Mar; 7(5):383-384
"It's not just the hit itself": the social practice of injecting drug use among gay and bisexual men in Australia.
Schroeder SE, Bourne A, Doyle J, Stoove M, Hellard M, Pedrana A
Int J Drug Policy. 2022 Mar; 103:103642
A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
Harney BL, Whitton B, Paige E, Brereton R, Weiss R, Membrey D, Wade AJ, Iser D, Kemp W, Roberts SK, Spelman T, Sacks-Davis R, Hellard ME, Doyle JS
Liver Int. 2022 Mar; 42(3):522-531
Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).
O'Keefe D, Gunn J, Ryan K, Djordjevic F, Kerr P, Gold J, Elsum I, Layton C, Chan K, Dietze P, Higgs P, Doyle J, Stoové MA, Hellard M, Pedrana AE
BMJ Open. 2022 Jan; 12(1):e057618
Screening for risky drinkers among hospitalised inpatients using the AUDIT: A feasibility, point prevalence and data linkage study.
O'Brien H, Di Rico R, Dean E, Smoker G, Lloyd-Jones M, McKechnie M, Dietze PM, Doyle JS
Drug Alcohol Rev. 2022 Jan; Epub ahead of print
High effectiveness of broad access direct-acting antiviral therapy for hepatitis C in an Australian real-world cohort: The REACH-C Study
Yee J, Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Doyle JS, Davies J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group.
Hepatol Commun. 2022 Jan; 6(3):496-512
Assessment of the cost-effectiveness of Australia’s risksharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study.
Scott N, Palmer A, Tidhar T, Stoové M, Sacks-Davis R, Doyle JS, Pedrana A, Thompson AJ, Wilson DP, Hellard M
Lancet Reg Health - West Pac. 2022 Jan; 18:100316
Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019.
Wilkinson AL, Pedrana A, Traeger MW, Asselin J, El-Hayek C, Nguyen L, Polkinghorne V, Doyle JS, Thompson AJ, Howell J, Scott N, Dimech W, Guy R, Hellard M, Stoové M; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of blood borne viruses and sexually transmissible infections (ACCESS)
Epidemiol Infect. 2022 Jan; 150:e7
The Incidence of Hepatitis C Among Gay, Bisexual, and Other Men Who Have Sex With Men in Australia, 2009-2019.
Harney BL, Sacks-Davis R, van Santen DK, Traeger M, Wilkinson AL, Asselin J, El-Hayek C, Fairley CK, Roth N, Bloch M, Matthews G, Donovan B, Guy R, Stoové M, Hellard ME, Doyle JS; Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Sexually Transmissible Infections and Blood-borne Viruses (ACCESS).
Clin Infect Dis. 2022 Jan; 74(10):1804-1811

2021 (18)

Assessing the feasibility, acceptability and impacts of an education program on hepatitis B testing uptake among ethnic Chinese in Australia: results of a randomised controlled pilot study.
Xiao Y, Wallace J, Ahad M, van Gemert C, Thompson AJ, Doyle J, Lam HY, Chan K, Bennett G, Adamson E, Yussf N, Tang A, Pedrana A, Stoove M, Hellard M, Howell J
BMC Public Health. 2021 Oct; 21(1):1861
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.
Carson JM, Hajarizadeh B, Hanson J, O'Beirne J, Iser D, Read P, Balcomb A, Davies J, Doyle JS, Yee J, Martinello M, Marks P, Dore GJ, Matthews GV; REACH-C Study Group
Int J Drug Policy. 2021 Oct; 96:103422
Letter in response: Psychiatrists can treat hepatitis C.
Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS
J Viral Hepat. 2021 Sep; 28(12):1765+1766
Early antimicrobial stewardship team intervention on appropriateness of antimicrobial therapy in suspected sepsis: a randomized controlled trial.
Rashidzada Z, Cairns KA, Peel TN, Jenney AW, Doyle JS, Dooley MJ, Cheng AC
JAC Antimicrob Resist. 2021 Aug; 3(3):dlab097
A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N; EC Partnership
J Viral Hepat. 2021 Aug; 28(11):1624-1634
Routine testing for syphilis and other bacterial sexually transmissible infections is required among people in prison.
Harney B, Doyle J, Hellard M, Stoové M, Winter R
Sex Transm Dis. 2021 Aug; 48(10):e153
Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study.
Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P; Treatment and Prevention Study group
Harm Reduct J. 2021 Jul; 18(1):73
"It's time!": A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C.
Walker S, Wallace J, Latham N, Saich F, Pedrana A, Hellard M, Treloar C, Marukutira T, Higgs P, Doyle J, Stoové M
Int J Drug Policy. 2021 May; 97:103280
Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
Goutzamanis S, Spelman T, Harney B, Dietze P, Stoové M, Higgs P, Thompson A, Doyle JS, Hellard M; Treatment, Prevention Study group.
J Viral Hepat. 2021 Apr; 28(7):1068-1077
Low incidence of hepatitis C among a cohort of HIV-negative gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Melbourne, Australia, and the contribution of sexual transmission.
Cornelisse VJ, Traeger MW, Wright EJ, Murphy D, Stoove M, Hellard M, Sacks-Davis R, Asselin J, Fairley CK, Doyle J, Sasawdeusz J
J Acquir Immune Defic Syndr. 2021 Mar; 87(4):1011-1015
Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
Harney BL, Brereton R, Whitton B, Pietrzak D, Paige E, Roberts SK, Birks S, Saraf S, Hellard ME, Doyle JS
J Viral Hepat. 2021 Feb; 28(5):771-778
In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
Wade AJ, Doyle JS, Draper B, Howell J, Iser D, Roberts SK, Kemp W, Thompson AJ, Hellard ME
J Viral Hepat. 2021 Jan; 28(1):217-218
The phases of hepatitis C elimination: achieving WHO elimination targets.
Pedrana A, Munari S, Stoové M, Doyle J, Hellard M
Lancet Gastroenterol Hepatol. 2021 Jan; 6(1):6-8
The case for simplifying and using absolute targets for viral hepatitis elimination goals
Polaris Observatory Collaborators (including Joseph Doyle)
J Viral Hepat. 2021 Jan; 28(1):12-19
Letter to the Editor: Recommendations for implementing hepatitis C virus care in homeless shelters: The stakeholder perspective.
Harney B, McColl R, Pedrana A, Morrison E, Doyle J, Hellard M, Higgs P
Hepatol Commun. 2021 Jan; 5(1):146-147
Peer to peer communication about hepatitis C treatment amongst people who inject drugs: A longitudinal qualitative study.
Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M; TAP study group
Int J Drug Policy. 2021 Jan; 87:102983
Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial.
Doyle JS, van Santen DK, Iser D, Sasadeusz J, O'Reilly M, Harney B, Traeger MW, Roney J, Cutts JC, Bowring AL, Winter R, Medland N, Fairley CK, Moore R, Tee B, Asselin J, El-Hayek C, Hoy JF, Matthews GV, Prins M, Stoové MA, Hellard ME
Clin Infect Dis. 2021 Jan; 73(7):e2164–e2172
Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.
Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, MacQuillan G, Dore GJ, Wade AJ, George J, Hazeldine S, O'Beirne J, Wigg A, Fisher L, McGarity B, Sawhney R, Sinclair M, Thomas J, Valiozis I, Weltman M, Wilson M, Woodward A, Ahlenstiel G, Haque M, Levy M, Prewett E, Sievert W, Sood S, Tse E, Valaydon Z, Bowden S, Douglas M, New K, O'Keefe J, Hellard M, Doyle J, Stoové M, Thompson AJ
Clin Infect Dis. 2021 Jan; 73(9):e3288-e3295

2020 (17)

Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
Papaluca T, Craigie A, McDonald L, Edwards A, MacIsaac M, Holmes JA, Jarman M, Lee T, Huang H, Chan A, Lai M, Sundararajan V, Doyle JS, Hellard M, Stoove M, Howell J, Desmond P, Iser D, Thompson A
PLoS One. 2020 Nov; 15(11):e0242101
Population patterns in Alcohol Use Disorders Identification Test (AUDIT) scores in the Australian population; 2007-2016.
O'Brien H, Callinan S, Livingston M, Doyle JS, Dietze PM
Aust N Z J Public Health. 2020 Oct; 44(6):462-467
Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.
Gupta RK, Calderwood CJ, Yavlinsky A, Krutikov M, Quartagno M, Aichelburg MC, Altet N, Diel R, Dobler CC, Dominguez J, Doyle JS, Erkens C, Geis S, Haldar P, Hauri AM, Hermansen T, Johnston JC, Lange C, Lange B, van Leth F, Muñoz L, Roder C, Romanowski K, Roth D, Sester M, Sloot R, Sotgiu G, Woltmann G, Yoshiyama T, Zellweger JP, Zenner D, Aldridge RW, Copas A, Rangaka MX, Lipman M, Noursadeghi M, Abubakar I
Nat Med. 2020 Oct; 26:1941-1949
Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV).
Byrne C, Radley A, Inglis SK, Beer LJZ, Palmer N, Pham MD, Healy B, Doyle JS, Donnan P, Dillon JF
BMJ Open. 2020 Aug; 10(8):e036501
The impact of markers of HIV infection on change in liver stiffness in people with HIV and hepatitis C virus co-infection after treatment and cure of hepatitis C.
van Santen DK, Agius PA, Sasadeusz J, Fairley KC, Sievert W, Gane E, Iser D, O'Reilly M, Medland NA, Moore R, Hellard ME, Hoy JF, Doyle JS
J Acquir Immune Defic Syndr. 2020 Aug; 85(5):e81-e89
A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available.
Gooey M, Wong E, Pedrana A, Allard N, Doyle J, Hellard M, Wade A
Sex Health. 2020 Aug; 17(4):387-389
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S, Martinello M, Yee J, Read P, Baker D, Post JJ, Finlayson R, Bloch M, Doyle JS, Shaw D, Hellard M, Petoumenos K, Carson J, Dore GJ, Matthews GV; CEASE study team
AIDS. 2020 Jul; 34(9):1347-1358
The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
Traeger MW, Pedrana AE, van Santen DK, Doyle JS, Howell J, Thompson AJ, El-Hayek C, Asselin J, Polkinghorne V, Membrey D, Bramwell F, Carter A, Guy R, Stoové MA, Hellard ME; EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
PLoS One. 2020 Jun; 15(6):e0235445
Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
van Santen DK, Sacks-Davis R, Doyle JS, Scott N, Prins M, Hellard M
J Viral Hepat. 2020 Mar; 27(8):770-773
Australia needs to increase testing to achieve hepatitis C elimination.
Scott N, Sacks-Davis R, Wade AJ, Stoové M, Pedrana A, Doyle JS, Thompson AJ, Wilson DP, Hellard ME
Med J Aust. 2020 Mar; 212(8):365-370
A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
Int J Drug Policy. 2020 Feb; 76:102633
Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection.
Scott N, Snell G, Westall G, Pilcher D, Raggatt M, Walker RG, Hellard M, Peleg AY, Doyle J
Sci Rep. 2020 Jan; 10(1):1459
Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure.
Stoové M, Wallace J, Higgs P, Pedrana A, Goutzamanis S, Latham N, Scott N, Treloar C, Crawford S, Doyle J, Hellard M
Int J Drug Policy. 2020 Jan; 75:102596
The Elimination of Hepatitis C as a Public Health Threat.
Hellard M, Schroeder SE, Pedrana A, Doyle J, Aitken C
Cold Spring Harb Perspect Med. 2020 Jan; 10(4):a036939
Commentary on Barre et al. (2019): Identifying remaining barriers to hepatitis C treatment in the DAA era.
Sacks-Davis R, van Santen DK, DoyleJS
Addiction. 2020 Jan; 115(3):583-584
Moving towards hepatitis C micro-elimination among people living with HIV in Australia: the CEASE study.
Martinello M, Yee J, Bartlett SR, Read P, Baker D, Post JJ, 7, 8, Finlayson R, Bloch M, Doyle J, Shaw D, Hellard M, Petoumenos K, Lin L, Marks P, Applegate T, Dore GJ, Matthews GV; CEASE study team
Clin Infect Dis. 2020 Jan; 71(6):1502-1510
Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Clin Infect Dis. 2020 Jan; 70(9):1900-1906

2019 (19)

Retreatment with Elbasvir, Grazoprevir, Sofosbuvir +/- Ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Papaluca T, Sinclair M, Gow P, Pianko S, Sievert W, Arachchi N, Cameron K, Bowden S, O'Keefe J, Doyle J, Stoove M, Hellard M, Iser D, Thompson A
Liver Int. 2019 Dec; 39(12):2285-2290
Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs.
Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R
Liver Int. 2019 Dec; 39(12):2244-2260
Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia
Papalucaa T, .O’Keefe J, Bowden S, Doyle JS, Stoové M, Hellard M, Thompson AJ
J Clin Virol. 2019 Oct; 120:84-87
Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people attending homeless services in Melbourne, Australia.
Harney BL, Whitton B, Lim C, Paige E, McDonald B, Nolan S, Pemberton D, Hellard ME, Doyle JS
Int J Drug Policy. 2019 Oct; 72:195-198
Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.
Hutton J, Doyle J, Zordan R, Weiland T, Cocco A, Howell J, Iser S, Snell J, Fry S, New K, Sloane R, Jarman M, Phan D, Tran S, Pedrana A, Williams B, Johnson J, Glasgow S, Thompson A
Int J Drug Policy. 2019 Oct; 72:84-90
Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study.
Williams B, Howell J, Doyle J, Thompson AJ, Draper B, Layton C, Latham N, Bramwell F, Membrey D, Mcpherson M, Roney J, Stoové M, Hellard ME, Pedrana A
Int J Drug Policy. 2019 Oct; 72:91-98
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.
Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K
Clin Liver Dis. 2019 Aug; 23(3):487-492
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients.
Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K
Clin Liver Dis. 2019 Aug; 23(3):493-509
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.
Sasadeusz J, Grigg A, Hughes PD, Lim SL, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K
Clin Liver Dis. 2019 Aug; 23(3):511-519
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Other Populations and Newer Agents.
Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K
Clin Liver Dis. 2019 Aug; 23(3):521-534
Australia’s progress towards hepatitis C elimination. Annual Report 2019
Burnet Institute and Kirby Institute (Prepared by Wilkinson A, Edited by Margaret Hellard M, Stoové, M, Dore G, Grebely J, Pedrana A, Doyle J, Thompson A, Hajarizadeh B, Alavi M, Aitken C)
Annual Report. 2019 Jul
Reducing alcohol-related harm in people recently treated for hepatitis C.
Hermosa S, Goutzamanis S , Doyle J, Higgs P
Aust J Prim Health. 2019 Jun; 25(3):193-194
Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement.
Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, Howell J, Hajkowicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ
Med J Aust. 2019 Jun; 210(10):462-468
Hepatitis C risk perceptions and attitudes towards reinfection among HIV-diagnosed gay and bisexual men in Melbourne, Australia.
Schroeder SE, Higgs P, Winter R, Brown G, Pedrana A, Hellard M, Doyle J, Stoové M
J Int AIDS Soc. 2019 May; 22(5):e25288
Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS, Scott N, Sacks-Davis R, Pedrana AE, Thompson AJ, Hellard ME; Eliminate Hepatitis C Partnership
Aliment Pharmacol Ther. 2019 Mar; 49(9):1223-1229
Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
Latham NH, Pedrana A, Doyle JS, Howell J, Williams B, Higgs P, Thompson AJ, Hellard ME
J Viral Hepat. 2019 Feb; 26(7):919-922
Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoové M, Hellard M, Iser D, Thompson A
J Hepatol. 2019 Jan; 70(5):839-846
Aiming for the elimination of viral hepatitis in Australia, New Zealand, the Pacific Islands and Territories: where are we now and barriers to meeting WHO targets by 2030.
Howell J, Pedrana A, Cowie BC, Doyle J, Getehun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME
J Gastroenterol Hepatol. 2019 Jan; 34(1):40-48
Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
Goutzamanis S, Doyle J, Higgs P, Hellard M
J Viral Hepat. 2019 Jan; 26(2):218-223

2018 (9)

Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
Scott N, Sacks-Davis R, Pedrana A, Doyle J, Thompson A, Hellard M
J Viral Hepat. 2018 Jul; 25(12):1472-1480
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Trials. 2018 Jul; 19(1):383
Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment?
Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME
Expert Rev Anti Infect Ther. 2018 May; 16(5):411-422
Experiences of liver health related uncertainty and self-reported stress among people who inject drugs living with hepatitis C virus: a qualitative study.
Goutzamanis S, Doyle JS, Thompson A, Dietze P, Hellard M, Higgs P; TAP study group.
BMC Infect Dis. 2018 Apr; 18(1):151
Hepatitis C Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment with Interferon-Free Regimens.
Stepanova M, Thompson A, Doyle J, Younossi I, de Avila L, Younossi ZM
J Infect Dis. 2018 Apr; 217(17):1033-1043
Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME
J Int AIDS Soc. 2018 Apr; 21 Suppl 2:e25051
Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.
Scott N, Hainsworth SW, Sacks-Davis R, Pedrana A, Doyle J, Wade A, Hellard M
J Virus Erad. 2018 Apr; 4(2):108-114
Effects of Pre-exposure Prophylaxis for the Prevention of HIV Infection on Sexual Risk Behavior in Men Who Have Sex with Men: A Systematic Review and Meta-analysis.
Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, Stoové MA
Clin Infect Dis. 2018 Mar; 67(5):676-686
Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour.
Scott N, Stoové M, Wilson DP, Keiser O, El-Hayek C, Doyle J, Hellard M
J Int AIDS Soc. 2018 Jan; 21(1):e25059

2017 (6)

Pathways to the elimination of hepatitis C: prioritising access for all.
Pedrana AE, Sacks-Davis R, Doyle JS, Hellard ME
Expert Rev Clin Pharmacol. 2017 Oct; 10(10):1023-1026
Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME
Int J Drug Policy. 2017 Sep; 47:107-116
New hepatitis C antiviral treatments eliminate the virus.
Doyle JS, Thompson AJ, Higgs P, Stoove M, Dietze PM, Hellard ME
Lancet. 2017 Jul; 390(10092):358-359
Injecting drug use in low and middle income countries: opportunities to improve care and prevent harm.
O'Keefe D, Stoové M, Doyle J, Dietze P, Hellard M.
J Viral Hepat. 2017 Jun; 24(9):714-724
A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.
Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, Hellard M
Aust Fam Physician. 2017 Apr; 46(4):235-240
Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME
Gut. 2017 Mar; 66(8):1507-1515

2016 (7)

Direct-acting antiviral treatment for HCV.
Goutzamanis S, Doyle J, Thompson A, Hellard M, Higgs P
Lancet Infect Dis. 2016 Dec; 16(12):1325-6
Field engagement further facilitates hepatitis B vaccination completion: Letter in response to: Day et al. (in press).
Higgs P, Doyle J, Luppi J, Dietze P, Hellard M
J Clin Virol. 2016 Jul; 82:64-65
Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort.
Doyle JS, Grebely J, Spelman T, Alavi M, Matthews GV, Thompson AJ, Dore GJ, Hellard ME; ATAHC Study Group.
PLoS One. 2016 Jun; 11(6):e0150655
Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks.
Hellard M, Sacks-Davis R, Doyle J
J Epidemiol Commun Health. 2016 Jun; 70:1151-1154
A systematic review of community based hepatitis C treatment.
Wade AJ, Veronese V, Hellard ME, Doyle JS.
BMC Infect Dis. 2016 May; 16(1):202
Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N, Iser D, Thompson A, Doyle J, Hellard M
J Gastroenterol Hepatol. 2016 Feb; 31(4):872-882
HIV and Sexual Risk Among Men Who Have Sex With Men and Women in Asia: A Systematic Review and Meta-Analysis.
Bowring AL, Veronese V, Doyle JS, Stoové M, Hellard M
AIDS Behav. 2016 Jan; 20(10):2243-2265

2015 (5)

The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME
PLoS One. 2015 Nov; 10(11):e0142770
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort.
Doyle JS, Deterding K, Grebely J, Wedemeyer H, Sacks-Davis R, Spelman T, Matthews G, Rice TM, Morris MD, McGovern BH, Kim AY, Bruneau J, Lloyd AR, Page K, Manns MP, Hellard ME, Dore GJ and the InC3 Study Group.
J Viral Hepat. 2015 Jun; 22(12):1020-1023
Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis.
Trauer JM, Qian MY, Doyle JS, W Rajaratnam SM, Cunnington D
Ann Intern Med. 2015 Jun; 163(3):191-204
Global policy and access to new hepatitis C therapies for people who inject drugs
Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME
Int J Drug Policy. 2015 Jun; 26(11):1064-1071
Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.
Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Falck-Ytter Y, Morgan RL, Smith B, Stoové M, Wiktor SZ, Hutchinson S
Eur J Epidemiol. 2015 Feb; 30(2):115-129

2014 (6)

Effects of HIV antiretroviral therapy on sexual and injecting risk-taking behaviour: a systematic review and meta-analysis.
Doyle JS, Degenhardt L, Pedrana AE, McBryde ES, Guy R, Stoové MA, Weaver E, Grulich AE, Lo YR, Hellard M
Clin Infect Dis. 2014 Aug; 59(10):1483-1494
A systematic review of immediate HCV RNA testing following HCV Antibody compared with HCV RNA testing at time of assessment for HCV therapy.
Hall K, Sacks-Davis R, Doyle J, Aspinall E, Hutchinson S, Hellard M
Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2014 Jul
Latent tuberculosis screening using interferon-gamma release assays in an Australian HIV-infected cohort: is routine testing worthwhile?
Doyle JS, Bissessor M, Denholm JT, Ryan N, Fairley CK, Leslie DE
J Acquir Immune Defic Syndr. 2014 Jan; 66(1):48-54
Eradication of hepatitis C infection: The importance of targeting people who inject drugs.
Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E
Hepatology. 2014 Jan; 59(2):366-369
Interferon-free hepatitis C treatment: one pill to fit all?
Hellard ME, Doyle J
Lancet. 2014 Jan; 383(9916):491-492
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis.
Aspinall EJ, Nambiar D, Goldberg DJ, Hickman M, Weir A, Van Velzen E, Palmateer N, Doyle JS, Hellard ME, Hutchinson SJ
Int J Epidemiol. 2014 Jan; 43(1):235-248

2013 (9)

Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis.
Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldberg DJ, Hellard ME
Clin Infect Dis. 2013 Aug; 57 Suppl 2:S80-S89
Direct acting antiviral therapy versus pegylated interferon and ribavirin treatment for chronic hepatitis C infection: a meta-analytical systematic review.
Doyle JS, Thompson AJ, Aspinall EJ, Hutchinson SJ, Hellard ME
Technical Report for the World Health Organisation, Global Hepatitis Programme. 2013 Jul
A systematic review of the effectiveness of antiviral treatment compared with no treatment for chronic HCV.
Doyle JS, Malandkar S, Aspinall EJ, Hall K, Hutchinson SJ, Hellard ME
Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
A systematic review and meta-analysis of targeted HCV antibody testing interventions.
Aspinall EJ, Doyle JS, Corson S, Hunt D, Hellard ME, Hutchinson SJ
Technical Report for World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
A systematic review of interventions to reduce alcohol consumption among individuals with chronic HCV infection.
Hunt D, Doyle JS, Aspinall EJ, Hutchinson SJ, Hellard ME
Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
Pegylated interferon plus ribavirin versus standard interferon plus ribavirin for chronic hepatitis C infection: a meta-analytical systematic review.
Quinn B, Doyle JS, Howell J, Chow SM, Aspinall EJ, Hutchinson SJ, Hellard ME
Technical Report for the World Health Organisation, Global Hepatitis Programme, Geneva. 2013 Jul
Beyond injecting drug use: investigation of a Victorian cluster of hepatitis C among HIV-infected men who have sex with men.
Mahony AA, Donnan EJ, Lester RA, Doyle JS, Knox J, Tracy SL, Bowden S, Sasadeusz JJ
Med J Aust. 2013 Mar; 198(4):210-214
Current and emerging antiviral treatments for hepatitis C infection.
Doyle JS, Aspinall E, Liew D, Thompson AJ, Hellard ME
Br J Clin Pharmacol. 2013 Mar; 75(4):931-43
Assessing the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.
Visconti AJ, Doyle JS, Weir A, Shiell AM, Hellard ME
J Gastroenterol Hepatol. 2013 Jan; 28(4):707-16

2012 (2)

The role of viral and host genetics in natural history and treatment of chronic HCV infection.
Doyle JS, Hellard ME, Thompson AJ
Best Pract Res Clin Gastroenterol. 2012 Aug; 26(4):413-427
Murray Valley encephalitis: a review of clinical features, diagnosis and treatment.
Knox J, Cowan RU, Doyle JS, Ligtermoet MK, Archer JS, Burrow JN, Tong SY, Currie BJ, Mackenzie JS, Smith DW, Catton M, Moran RJ, Aboltins CA, Richards JS
Med J Aust. 2012 Mar; 196(5):322-326

2011 (3)

Epidemiology of infections acquired in intensive care units.
Joseph S Doyle, Kirsty L Buising, Karin A Thursky, Leon J Worth, Michael J Richards
Semin Respir Crit Care Med. 2011 Apr; 32(2):115-138
Mumps presenting as epididymo-orchitis among young travellers: under-recognition, missed diagnoses and transmission risks.
Joseph S Doyle, Emma K Paige, Denis W Spelman
Med J Aust. 2011 Mar; 194(6):317-318
Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy.
Doyle JS, Campbell E, Fuller A, Spelman DW, Cameron R, Malham G, Gin D, Lewin SR
J Neurosurg. 2011 Feb; 114(2):458-462

News Articles (38)

2022 (1)

A QuickStart to treatment for hepatitis C

2021 (3)

2020 (7)

2019 (7)

2018 (4)

2017 (4)

2016 (9)

2014 (3)

Contact Details

Telephone

+61385062324

Email

joseph.doyle@burnet.edu.au

Working Group

Viral Hepatitis Elimination Group

Programs

Discipline

Public Health

Support Us

About

People

Research

COVID-19

Changing Lives

Opportunities